Glucose
Product Images NDC 0338-9785

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Glucose (NDC 0338-9785). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dhcp Letter 1 Of 7 (Image 01)

This document is an important prescribing information letter from Baxter Healthcare Company dated October 18, 2024. It addresses the temporary importation of 50% and 70% Glucose Injection from the United Kingdom due to drug shortages. The letter informs healthcare professionals that these products are imported from Baxter's manufacturing facility in Thetford, UK, and are not FDA approved. It highlights that Baxter is the only authorized entity by the FDA to import and distribute these products in the US during this period.*

FDA Label Image

Dhcp Letter 2 Of 7 (Image 02)

A data table listing two Glucose Injection products by Baxter Healthcare Company, showing product name, size, product code, bags per carton, and NDC code of a single bag. It includes 50% Glucose Injection (3,000 mL, 4 bags per carton) and 70% Glucose Injection (500 mL, 20 bags per carton). Below the table are notes clarifying non-interchangeability with FDA-approved Dextrose Injection USP and differences in energy content per mL.*

FDA Label Image

Dhcp Letter 3 Of 7 (Image 03)

This text panel provides handling and safety instructions for Baxter Healthcare Company's glucose injection products. It advises inspecting bags for particulate matter or defects, states the imported products are not for direct patient administration, confirms compatibility with Baxter sets in the U.S., notes the absence of barcodes on imported unit labels, and mentions prescription status differences for dextrose and glucose injections.*

FDA Label Image

Dhcp Letter 4 Of 7 (Image 04)

A text excerpt featuring references to tables comparing FDA-approved 70% Dextrose Injection USP with imported 70% and 50% Glucose Injection products. It includes notes on UK prescribing information for concentrated Glucose Injection formulations and links to prescribing information for both Glucose and Dextrose Injection products.*

FDA Label Image

Dhcp Letter 5 Of 7 (Image 05)

This document provides information on reporting adverse events or product quality issues related to Baxter Healthcare Company's imported Glucose products. It includes contact details for Baxter's reporting lines, FDA MedWatch reporting, and Baxter's Product Feedback Portal. The letter is signed by Lee Ann Schuette, Vice President of Global and US Marketing IV solutions, Clinical Nutrition, Pharmacy Tools at Baxter Healthcare Corporation.*

FDA Label Image

Dhcp Letter 6 Of 7 (Image 06)

A comparison table showing key differences among FDA-approved 70% Dextrose Injection USP and two imported UK products of 70% and 50% Glucose Injection. The table details product names, label volumes, indications, active ingredients, caloric content, additional information such as pH and osmolarity, storage conditions, container type, and images of administration port closures with color-coded protectors.*

FDA Label Image

Dhcp Letter 7 Of 7 (Image 07)

Table showing label images of FDA-approved 70% Dextrose Injection USP and imported 70% and 50% Glucose Injection products from the UK by Baxter Healthcare. Labels include color information, volume, warnings about dilution and direct infusion, and formulation details. The FDA-approved product uses a fully blue label, while imported products use black labels with 70% or 50% concentration prominently displayed.*

FDA Label Image

Container Label 0338-9787-01 (Image 08)

Label for Baxter Glucose 50% w/v concentrate for solution for infusion in a 3000 ml VIAFLEX container. The hypertonic solution contains 500 g anhydrous glucose per 1000 ml, water for injections, and HCl for pH adjustment. The label includes warnings to dilute before use, not to use for direct intravenous infusion, and storage instructions. Manufacturer is Baxter Healthcare Ltd.*

FDA Label Image

Carton Label 0338-9878-01 (Image 09)

Label for Baxter Glucose 50% w/v concentrate for solution for infusion. The label indicates a hypertonic solution with a volume of 4 x 3000 ml, approximately 15.5 kg. Storage instructions specify not to store above 25°C and to keep out of reach of children. The labeler is Baxter Healthcare Ltd, UK.*

FDA Label Image

Container Label 0338-9785-01 (Image 10)

Label for Baxter Glucose 70% w/v Concentrate for solution for infusion, 500 ml container. The label indicates anhydrous glucose 700 g per 1000 ml and includes dilution and usage instructions. It is a hypertonic solution supplied in a Viaflex container by Baxter Healthcare Company.*

FDA Label Image

Carton Label 0338-9785-01 (Image 11)

Label for Glucose 70% w/v Concentrate for solution for infusion by Baxter Healthcare Company. The label indicates a 20 x 500 ml package size, classified as hypertonic, with storage instructions and manufacturer details listed. The product is marked for infusion use with a prominent 70% concentration display.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.